Actualización del abordaje farmacológico de la enfermedad esteatosica asociada a disfunción metabólica

Abstract

Background: metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition with high prevalence and morbimortality, considered a public health problem, which not only affects individual health and family economy, but has also had a great impact on the costs of health care systems worldwide. Objective: to describe the update of the pharmacological approach to steatotic disease associated with metabolic dysfunction. Methodology: a narrative literature review was carried out including 20 scientific articles, selected from different databases such as Medline, Lilacs, TripDataBase, Cochrane Library, Epistemonikos. Results: MASLD is closely linked to cardiovascular diseases, which highlights the importance of holistic approaches and prevention strategies adapted to different populations. In addition, progress is being made in the treatment of MASLD, exploring hypoglycemic drugs and agents such as GLP-1 to reduce hepatic fat accumulation. Therapeutic approaches including miRNA-34a inhibition, PPAR agonists, L-carnitine supplementation and gut microbial therapies are also being considered. These advances offer hope for improving the quality of life of MASLD patients and reventing serious complications. However, more research is needed to fully understand the long-term impact and efficacy of these therapies.